Literature DB >> 11597571

Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain.

K A Schoedel1, E M Sellers, R F Tyndale.   

Abstract

A higher proportion of alcoholics than non-alcoholics smoke (>80 vs 30%). In animals, chronic administration of alcohol induces tolerance to some effects of nicotine. To investigate if chronic ethanol (EtOH) induces alterations in CYP2B1/2 and nicotine C-oxidation activity, male rats (N = 4-6/group) were treated once daily with saline or EtOH (0.3, 1.0, and 3.0 g/kg, p.o./by gavage) for 7 days. A quantitative immunoblotting assay was developed to detect CYP2B1/2 in the brain, where constitutive expression is low, and in the liver. Using this method, it was determined that EtOH did not alter CYP2B1/2 protein expression significantly in six brain regions (olfactory bulbs, olfactory tubercles, frontal cortex, hippocampus, cerebellum, and brainstem). However, a dose-dependent induction of CYP2B1/2 protein expression was detected in the liver. Significant induction of 2-, 3-, and 2.7-fold were observed for the 0.3, 1.0, and 3.0 g/kg doses, respectively. Increases were also observed in CYP2B1 mRNA, which was induced by 14, 38, and 43% at the same doses. Liver microsomal nicotine C-oxidation also was increased (1.3 to 4.5-fold). CYP2B selective inactivators demonstrated that approximately 70% of nicotine C-oxidation was mediated by CYP2B1/2 in both EtOH-induced and uninduced hepatic microsomes. In summary, chronic, behaviorally relevant doses of EtOH induce CYP2B1/2 protein, mRNA, and nicotine C-oxidation activity in rat liver but not in rat brain, and these increases could contribute to cross-tolerance and co-abuse of ethanol and nicotine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11597571     DOI: 10.1016/s0006-2952(01)00744-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

Review 1.  Drug-metabolizing cytochrome P450s in the brain.

Authors:  Sharon L Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

2.  Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2008-07-30       Impact factor: 7.853

Review 3.  Cytochrome P450-mediated drug metabolism in the brain.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

4.  Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor.

Authors:  Shakir D Alsharari; Eric C K Siu; Rachel F Tyndale; Mohamad Imad Damaj
Journal:  Nicotine Tob Res       Date:  2013-07-24       Impact factor: 4.244

5.  Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake.

Authors:  Jiang Yue; Jibran Khokhar; Sharon Miksys; Rachel F Tyndale
Journal:  Eur J Pharmacol       Date:  2009-03-13       Impact factor: 4.432

6.  Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model.

Authors:  Xin Zhou; Xiaoliang Zhuo; Fang Xie; Kerri Kluetzman; Yue-Zhong Shu; W Griffith Humphreys; Xinxin Ding
Journal:  J Pharmacol Exp Ther       Date:  2009-11-18       Impact factor: 4.030

7.  Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5.

Authors:  Eric C K Siu; Dieter B Wildenauer; Rachel F Tyndale
Journal:  Psychopharmacology (Berl)       Date:  2006-01-28       Impact factor: 4.530

Review 8.  Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.

Authors:  Guillermo Gervasini; Juan Antonio Carrillo; Julio Benitez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Effect of status epilepticus and antiepileptic drugs on CYP2E1 brain expression.

Authors:  B Boussadia; C Ghosh; C Plaud; J M Pascussi; F de Bock; M C Rousset; D Janigro; N Marchi
Journal:  Neuroscience       Date:  2014-10-02       Impact factor: 3.590

10.  Effect of Gestational Exposure of Cypermethrin on Postnatal Development of Brain Cytochrome P450 2D1 and 3A1 and Neurotransmitter Receptors.

Authors:  Anshuman Singh; Anubha Mudawal; Rajendra K Shukla; Sanjay Yadav; Vinay K Khanna; Rao Sethumadhavan; Devendra Parmar
Journal:  Mol Neurobiol       Date:  2014-10-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.